Received: 9 June 2020
Accepted: 9 December 2020
First Online: 28 April 2021
Ethics approval and consent to participate
: Ethics approval and patient consents were not required for this study since no personal information was used and no human experiment conducted. All data have been deidentified for the purpose of this publication.
: Not applicable. Consent to publish was not required for this study since no personal information was used and no human experiment conducted.
: SS received a travel award to present this data as a poster in the Hyperinsulinism symposium conducted at Children’s Hospital of Philadelphia in September 2019. MAS is a consultant for the insulin advisory board for Novo Nordisk. JG has no competing interests. CR is a consultant for the Ascendis Advisory Board.